Forest CEO: Aptalis a `Compelling Opportunity'
Jan. 8 (Bloomberg) -- Brent Saunders, chief executive officer of Forest Laboratories Inc., talks about the company's agreement to acquire Aptalis Pharma for $2.9 billion in cash. Aptalis is a closely held company whose shareholders include investment firm TPG Capital. Saunders speaks with Betty Liu on Bloomberg Television's "In the Loop." (Source: Bloomberg)
Most Recent Videos
Australia PM Turnbull to Curb Gas Exports
47:43 - Bloomberg's Paul Allen reports on the latest business news in Australia. He speaks on "Bloomberg Daybreak: Australia." (Source: Bloomberg)